治疗性结肠炎的Etrasimod:一个全面的审查
Osman Cagin Buldukoglu1, Yusuf Erzin2, Ayhan Hilmi Cekin1
1Department of Gastroenterology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Türkiye.
概括
性结肠炎 (UC) 管理面临着当前治疗方法的挑战. 本综述详细介绍了先进的治疗方法,重点关注Etrasimod,这是一种用于UC的新型斯芬戈-1-酸盐受体 (S1PR) 调节器.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性结肠疾病,具有不可预测的,令人虚弱的症状.
- 目前的治疗方法,包括5-aminosalicylic acid (5-ASA),有局限性,许多患者经历了治疗失败或反应丧失.
- 先进的疗法对于管理严重或耐火性UC至关重要.
研究的目的:
- 为提供关于性结肠炎 (UC) 当前医疗治疗选择的概述.
- 详细介绍埃特拉西莫德的分子和临床方面,这是一个基-1-酸盐受体 (S1PR) 调节器.
- 突出针对UC患者的新兴治疗方法,这些患者对传统疗法没有反应.
主要方法:
- 对UC的当前药物治疗方法的文献综述.
- 对S1PR调节器的分子机制和临床数据的分析.
- 综合有关UC管理中先进治疗策略的信息.
主要成果:
- 目前的UC药物治疗包括5-ASA,瘤亡因子-α抑制剂 (TNFi),抗整合素,抗介质蛋白,Janus激酶 (JAK) 抑制剂和S1PR调节剂.
- 作为治疗UC的S1PR调节器,Etrasimod是一个重要的发展.
- 很大一部分患者对现有的治疗方法没有反应,需要新的治疗方法.
结论:
- 埃特拉西莫德作为UC的先进疗法具有前景,准S1PR通路.
- 审查强调了需要在UC多样化和有效的治疗选择.
- 优化UC管理需要了解新型药物的作用,如Etrasimod.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
61
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
61